Despite the growing body of evidence for increased adenosine levels and upregulation of A2AR levels in human ALS and ALS models (Table 2), pharmacological outcomes, using both A2A agonists/antagonists, vary considerably (Table 3). Here, ADORA2A is linked to amyotrophic lateral sclerosis.